4507   Shionogi & Co.,Ltd.

04/25/2024 15:00	Notice of Revisions to Dividend Forecasts (Dividend Increase)
04/23/2024 17:00	Notice regarding introduction of a Restricted Stock Compensation Plan for Vice Presidents
04/18/2024 11:30	Notice Regarding Completion of Cancellation of Treasury Shares
03/28/2024 16:00	Notice Regarding the Status and Completion of Acquisition of Own Shares
03/05/2024 15:00	Shionogi Announces Xocova (Ensitrelvir Fumaric Acid) Obtained Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection
03/05/2024 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
02/06/2024 16:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
01/31/2024 13:00	3rd Quarter of Fiscal 2023 Financial Results
01/31/2024 13:00	Supplemental material for financial results for the 3rd quarter of fiscal year 2023
01/31/2024 13:00	Consolidated Financial Results for the Third Quarter of Fiscal Year 2023 (IFRS)
01/10/2024 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
12/20/2023 11:30	New Siderophore Cephalosporin Antibiotic Fetroja Launches in Japan, Along with the Release of Reagents for Antimicrobial Susceptibility Testing
12/18/2023 11:30	Initiation of a Phase 3 Additional Dose Clinical Trial in Japanese Subjects of the Monovalent Vaccine for the XBB1.5 Strain, S-268023
12/07/2023 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
11/30/2023 15:00	Regarding the Acquisition of Manufacturing and Marketing Approval for the New Siderophore Cephalosporin Antibiotic Fetroja(cefiderocol)
11/08/2023 16:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
10/31/2023 13:00	1st Half of Fiscal 2023 Financial Results
10/31/2023 13:00	Financial Results for the Second Quarter of Fiscal Year 2023
10/31/2023 13:00	Consolidated Finacial Results for the Second Quarter of Fiscal Year 2023 (IFRS)
10/06/2023 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
09/04/2023 15:00	Notice Regarding the Status (Progress Report) of Acquisition of Own Shares
07/31/2023 15:00	1st Quarter of Fiscal 2023 Financial Results
07/31/2023 15:00	Supplemental material for financial results for the 1st quarter of fiscal year 2023
07/31/2023 15:00	Consolidated Financial Results for the First Quarter of Fiscal Year 2023 (IFRS)
07/31/2023 15:00	Notice Regarding Acquisition of Own Shares and Cancellation of Treasury Shares
07/20/2023 16:00	Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan
07/10/2023 15:00	Notice Regarding Implementation of an Early Retirement Program
06/30/2023 15:00	Corporate Governance Report 20230630
06/30/2023 11:30	Eddingpharm Announces Approval of Mulpleta (Lusutrombopag) in China
06/29/2023 11:30	Initiation of a Phase 3 Clinical Trial in Japanese Pediatric Patients of Ensitrelvir for COVID-19
06/26/2023 08:30	Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
06/21/2023 17:00	Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan
06/09/2023 15:30	Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
06/01/2023 12:00	Medium-Term Business Plan SHIONOGI Transformation Strategy 2030 (STS2030) Revision
06/01/2023 12:00	Revision of the Medium-Term Business Plan STS2030- Accelerating the transition to global growth to achieve our 2030 Vision -
05/25/2023 08:00	Notice of Convocation of Annual General Meeting and Meeting Materials 2023
05/10/2023 13:00	FY2022 Financial Results
05/10/2023 13:00	Consolidated Financial Results for Fiscal Year 2022 (IFRS)
05/10/2023 13:00	Financial results for the year ended March 31, 2023